Compare · ERNA vs NVO
ERNA vs NVO
Side-by-side comparison of Ernexa Therapeutics Inc. (ERNA) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ERNA and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.82B, about 32890.9x ERNA ($5.6M).
- Over the past year, ERNA is down 93.9% and NVO is down 34.2% - NVO leads by 59.7 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 1 for ERNA).
- NVO has more recent analyst coverage (25 ratings vs 0 for ERNA).
- Company
- Ernexa Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $0.19+1.21%
- $41.18+6.93%
- Market cap
- $5.6M
- $183.82B
- 1M return
- -5.57%
- +13.32%
- 1Y return
- -93.91%
- -34.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 5
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ERNA
- SEC Form DEF 14C filed by Ernexa Therapeutics Inc.
- SEC Form PRE 14C filed by Ernexa Therapeutics Inc.
- Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026
- SEC Form EFFECT filed by Ernexa Therapeutics Inc.
- Amendment: SEC Form S-3/A filed by Ernexa Therapeutics Inc.
- SEC Form 8-K filed by Ernexa Therapeutics Inc.
- SEC Form 10-K filed by Ernexa Therapeutics Inc.
- Ernexa Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
- Large owner Cherington Charles bought $2,000,000 worth of shares (4,000,000 units at $0.50), increasing direct ownership by 144% to 6,779,440 units (SEC Form 4)
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S